These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19175989)

  • 1. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
    Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MPLW515L point mutation in patients with myeloproliferative disease].
    Xia J; Xu W; Zhang SJ; Fan L; Qiao C; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1421-4. PubMed ID: 19099657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
    Ruan GR; Chen SS; Li LD; Liu YR; Qin YZ; Li JL; Ma X; Wang FR; Jiang Q; Jiang B; Liu KY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2401-4. PubMed ID: 18036317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation.
    Hussein K; Theophile K; Buhr T; Beller A; Kreipe H; Bock O
    Br J Haematol; 2009 Jun; 145(5):673-5. PubMed ID: 19344408
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.
    Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H
    Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The clinical implication of JAK2 mutation expression in patients with myeloproliferative disorders].
    Fei HR; Zhang R; Chen SN; Pan JL; Cen JN; Xue YQ
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):271-3. PubMed ID: 17637260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
    Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
    Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause.
    Strobbe L; Lestrade P; Hermans MH; Fijnheer R
    Ann Hematol; 2007 Nov; 86(11):801-3. PubMed ID: 17703302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
    Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
    Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
    Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.
    Pardanani A; Lasho TL; Finke C; Mesa RA; Hogan WJ; Ketterling RP; Gilliland DG; Tefferi A
    Stem Cells; 2007 Sep; 25(9):2358-62. PubMed ID: 17540852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
    Zhu JF; Liu Y; Liu P; Jia MF; Cheng J; Zhao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):916-20. PubMed ID: 21867614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms.
    Goette NP; Lev PR; Heller PG; Kornblihtt LI; Korin L; Molinas FC; Marta RF
    Cytokine; 2010 Jul; 51(1):67-72. PubMed ID: 20483636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tyrosine kinase JAK2V617F mutation in human myeloproliferative disorders].
    Xu YY; Li HM; Li XJ; Yang L; Hu DM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):541-4. PubMed ID: 19549360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.